What is the appropriate management for a heparin-induced transfusion reaction?

Management of Heparin-Induced Thrombocytopenia

Immediately discontinue all heparin (including heparin flushes) and start a non-heparin anticoagulant at therapeutic doses, even before confirmatory testing returns. This is the single most critical intervention to prevent life-threatening thrombosis 1.

Immediate Actions

When HIT is suspected or confirmed:

• Stop all heparin exposure immediately - this includes unfractionated heparin, low-molecular-weight heparin, and heparin line flushes 2, 1
• Do NOT wait for laboratory confirmation to discontinue heparin and initiate alternative anticoagulation 1
• Avoid platelet transfusions unless there is active life-threatening bleeding, as they may paradoxically increase thrombosis risk 2
• Do NOT start warfarin or other vitamin K antagonists until platelet count recovers to ≥150 × 10⁹/L, as early warfarin use is associated with venous limb gangrene 2

Choice of Non-Heparin Anticoagulant

The 2018 ASH guidelines recommend several options 1:

For critically ill or unstable patients:

• Argatroban or bivalirudin are preferred due to their short half-lives, allowing rapid reversal if urgent procedures or bleeding occurs
• Argatroban requires dose reduction in moderate-to-severe liver dysfunction (Child-Pugh B or C)
• These agents require close monitoring and continuous infusion

For stable patients without high bleeding risk:

• Fondaparinux or direct oral anticoagulants (DOACs) are reasonable first-line options
• Rivaroxaban has the most published experience among DOACs in HIT 1
  • For HIT with thrombosis: 15 mg twice daily for 3 weeks, then 20 mg once daily
  • For isolated HIT: 15 mg twice daily until platelet recovery, then 20 mg once daily if ongoing anticoagulation needed
• DOACs offer ease of administration, cost-effectiveness, and eliminate the need for bridging therapy

Danaparoid is another option but availability varies by region 1

Critical Pitfalls to Avoid

1. Do not give prophylactic-dose anticoagulation - therapeutic-intensity anticoagulation is required even in isolated HIT without thrombosis, as the risk of developing thrombosis is 30-50% 2, 1

2. Do not transition to warfarin prematurely - wait until platelets recover to ≥150 × 10⁹/L and overlap for minimum 5 days to prevent warfarin-induced venous limb gangrene 2

3. Do not place IVC filters routinely - these may increase thrombosis risk in HIT patients 3

4. Do not use low-molecular-weight heparin as an alternative - it has high cross-reactivity with HIT antibodies 2

Duration of Anticoagulation

• HIT with thrombosis: Treat for 3 months minimum 3
• Isolated HIT without thrombosis: Continue therapeutic anticoagulation until platelet count recovery, then discontinue if no other indication exists 1, 3

Special Considerations

The pathophysiology involves IgG antibodies against platelet factor 4-heparin complexes that activate platelets, generating massive thrombin and causing both arterial and venous thrombosis 2. This explains why thrombocytopenia paradoxically increases thrombosis risk rather than bleeding risk.

Unfractionated heparin carries 10-fold higher HIT risk than LMWH, with surgical patients (especially cardiac and orthopedic) at highest risk (1-5%) compared to medical patients (0.1-1%) 2. Women have approximately twice the risk of men 2.

The evidence strongly supports immediate action over waiting for confirmatory testing, as delays in switching to non-heparin anticoagulation significantly increase morbidity and mortality from thrombotic complications 2, 1.